Posted by Michael Wonder on 20 Jul 2021
Albireo announces FDA approval of Bylvay (odevixibat), the first drug treatment for patients with progressive familial intrahepatic cholestasis
20 July 2021 - Commercial launch of Bylvay immediate; available for prescription in the coming days.
Albireo Pharma today announced U.S. FDA approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in all sub-types of progressive familial intrahepatic cholestasis.
